Christopher Mutz Sells 417 Shares of ANI Pharmaceuticals (NASDAQ:ANIP) Stock

ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) insider Christopher Mutz sold 417 shares of the business’s stock in a transaction that occurred on Monday, March 2nd. The shares were sold at an average price of $74.00, for a total transaction of $30,858.00. Following the transaction, the insider owned 103,508 shares of the company’s stock, valued at approximately $7,659,592. This represents a 0.40% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink.

Christopher Mutz also recently made the following trade(s):

• On Friday, February 20th, Christopher Mutz sold 5,323 shares of ANI Pharmaceuticals stock. The shares were sold at an average price of $78.02, for a total transaction of $415,300.46.

ANI Pharmaceuticals Stock Down 1.2%

Shares of NASDAQ:ANIP opened at $75.60 on Friday. ANI Pharmaceuticals, Inc. has a 52-week low of $56.71 and a 52-week high of $99.50. The company has a market capitalization of $1.70 billion, a PE ratio of 22.50 and a beta of 0.52. The company has a debt-to-equity ratio of 1.11, a quick ratio of 2.19 and a current ratio of 2.71. The company has a fifty day moving average of $79.83 and a 200-day moving average of $86.04.

Institutional Inflows and Outflows

A number of institutional investors have recently made changes to their positions in the company. Advisors Asset Management Inc. purchased a new stake in shares of ANI Pharmaceuticals during the 1st quarter valued at approximately $28,000. Hantz Financial Services Inc. grew its stake in ANI Pharmaceuticals by 202.6% in the 3rd quarter. Hantz Financial Services Inc. now owns 354 shares of the specialty pharmaceutical company’s stock valued at $32,000 after buying an additional 237 shares in the last quarter. Newbridge Financial Services Group Inc. raised its holdings in ANI Pharmaceuticals by 200.0% during the 2nd quarter. Newbridge Financial Services Group Inc. now owns 600 shares of the specialty pharmaceutical company’s stock valued at $39,000 after acquiring an additional 400 shares during the period. Kemnay Advisory Services Inc. purchased a new stake in shares of ANI Pharmaceuticals during the fourth quarter worth $48,000. Finally, State of Wyoming purchased a new stake in shares of ANI Pharmaceuticals during the second quarter worth $50,000. Hedge funds and other institutional investors own 76.05% of the company’s stock.

Analysts Set New Price Targets

A number of brokerages recently issued reports on ANIP. Barclays assumed coverage on ANI Pharmaceuticals in a report on Tuesday, December 9th. They issued an “overweight” rating and a $100.00 target price on the stock. Weiss Ratings reiterated a “hold (c+)” rating on shares of ANI Pharmaceuticals in a report on Monday, December 29th. Guggenheim boosted their target price on shares of ANI Pharmaceuticals from $115.00 to $124.00 and gave the stock a “buy” rating in a research report on Friday, January 16th. Finally, Zacks Research lowered shares of ANI Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a report on Tuesday, January 6th. Six equities research analysts have rated the stock with a Buy rating and three have issued a Hold rating to the company. According to data from MarketBeat, ANI Pharmaceuticals presently has an average rating of “Moderate Buy” and an average price target of $103.43.

About ANI Pharmaceuticals

ANI Pharmaceuticals, Inc is a United States–based specialty pharmaceutical company focused on the development, manufacturing and commercialization of generic and branded prescription drugs. The company operates as an end-to-end provider, offering services that range from active pharmaceutical ingredient (API) production and formulation development to finished dosage form manufacturing and packaging.

ANI’s product portfolio encompasses injectable and oral therapies across several therapeutic areas, including endocrinology, oncology, pain management and respiratory care.